Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587 is registered in ClinicalTrials.gov with IDEAYA Biosciences as lead sponsor.

NCT NCT05787587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05787587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Lead sponsor
IDEAYA Biosciences
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 18, 2023
Completion date
May 31, 2027
Enrollment
216 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, breast cancer, colorectal cancer, endometrial cancer, extensive stage small cell lung cancer (es-sclc), head and neck cancers, nsclc, ovarian cancer, prostate cancer